1. Home
  2. KYTX vs MCHX Comparison

KYTX vs MCHX Comparison

Compare KYTX & MCHX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KYTX
  • MCHX
  • Stock Information
  • Founded
  • KYTX 2018
  • MCHX 2003
  • Country
  • KYTX United States
  • MCHX United States
  • Employees
  • KYTX N/A
  • MCHX N/A
  • Industry
  • KYTX
  • MCHX Business Services
  • Sector
  • KYTX
  • MCHX Consumer Discretionary
  • Exchange
  • KYTX NYSE
  • MCHX Nasdaq
  • Market Cap
  • KYTX 92.1M
  • MCHX 84.3M
  • IPO Year
  • KYTX 2024
  • MCHX 2004
  • Fundamental
  • Price
  • KYTX $2.55
  • MCHX $1.60
  • Analyst Decision
  • KYTX Strong Buy
  • MCHX
  • Analyst Count
  • KYTX 5
  • MCHX 0
  • Target Price
  • KYTX $19.00
  • MCHX N/A
  • AVG Volume (30 Days)
  • KYTX 382.4K
  • MCHX 28.5K
  • Earning Date
  • KYTX 05-13-2025
  • MCHX 05-13-2025
  • Dividend Yield
  • KYTX N/A
  • MCHX N/A
  • EPS Growth
  • KYTX N/A
  • MCHX N/A
  • EPS
  • KYTX N/A
  • MCHX N/A
  • Revenue
  • KYTX N/A
  • MCHX $47,951,000.00
  • Revenue This Year
  • KYTX N/A
  • MCHX $6.83
  • Revenue Next Year
  • KYTX N/A
  • MCHX N/A
  • P/E Ratio
  • KYTX N/A
  • MCHX N/A
  • Revenue Growth
  • KYTX N/A
  • MCHX N/A
  • 52 Week Low
  • KYTX $1.78
  • MCHX $1.26
  • 52 Week High
  • KYTX $16.64
  • MCHX $2.40
  • Technical
  • Relative Strength Index (RSI)
  • KYTX 57.07
  • MCHX 51.66
  • Support Level
  • KYTX $2.43
  • MCHX $1.57
  • Resistance Level
  • KYTX $2.82
  • MCHX $1.74
  • Average True Range (ATR)
  • KYTX 0.23
  • MCHX 0.14
  • MACD
  • KYTX 0.04
  • MCHX 0.01
  • Stochastic Oscillator
  • KYTX 64.47
  • MCHX 55.81

About KYTX KYVERNA THERAPEUTICS INC

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

About MCHX Marchex Inc. Class B

Marchex Inc is a conversational analytics and solutions company that helps businesses connect, drive, measure, convert callers into customers, and connect the voice of the customer to their business. It delivers data insights and incorporates artificial intelligence (AI)-powered functionality that drives insights and solutions to help companies find, engage, and support their customers across voice and text-based communication channels. The group enables sales and marketing teams to deliver the buying experiences that today's customers expect. The company generates the majority of its revenues from core analytics and solutions services. The company operates in the United States, Canada, and other countries.

Share on Social Networks: